Using Heavy Water to Study Cell Dynamics in Parkinson's Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This pilot study will assess the feasibility of using heavy water as a safe 'tracer' for biomarker studies of diseases of the brain and spinal cord, that, together, are also called the central nervous system (CNS). Heavy water, also called deuterated water or D20, is the same as normal drinking water except the hydrogen atoms have been replaced by deuterium, a naturally occurring isotope of hydrogen. In particular, this study will use heavy water to define: 1) The rate of immune cell proliferation (growth) in the cerebrospinal fluid (CSF) compared to blood. This study will be examining a particular type of immune cell called T lymphocytes. 2) This study will also examine selected molecules generated by nerve cells of the CNS to understand their rate of secretion and turnover in healthy control participants, HIV-1-infected participants and participants with a non-HIV-related neurodegenerative disease such as Parkinson's disease (PD).
This study will involve the administration of heavy water orally for either seven days, 12 days or six weeks. Measurements will be taken by lumbar puncture (LP, also known as a spinal tap). Blood (approximately five tablespoons per visit) will also be obtained at each of the lumbar puncture appointments.
If this method can be used to establish the rates of immune cell turnover and the production rates of neuronal molecules using cerebrospinal fluid, it will provide unique data that is important to understand chronic neurodegenerative conditions, like PD, and to measure responses to targeted therapies.
Hypothesis:
- D2O, administered orally, can be used to measure the proliferation rates of CSF T cells (and, eventually, of their major phenotypic subsets).
- D2O can be used to assess the turnover and production rates of CNS constituents that are normally or pathologically shed or secreted into the CSF, including (eventually): cargo molecules transported specifically in neurons in the CNS, such as chromogranin-A and -B, neuregulin-1 (specifically the extracellular secreted ectodomain of neuronal differentiation factor (NDF) isoform type α1, α2, β1, and the acetylcholine receptor inducing activity isoform (ARIA), secreted amyloid precursor protein (sAPP), alpha-synuclein; and APP metabolites amyloid beta (Aβ) 41 and 42.
| Condition |
|---|
|
Parkinson's Disease HIV Infections |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort |
| Official Title: | Cellular and Molecular Kinetics of Cerebrospinal Fluid (CSF) Using Heavy Water Labeling Method: A Study of Healthy Controls, CNS HIV Infection, Parkinson's Disease and Other Neurodegenerative Diseases |
plasma
| Estimated Enrollment: | 24 |
| Study Start Date: | April 2009 |
| Estimated Study Completion Date: | February 2013 |
| Estimated Primary Completion Date: | February 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Controls
Healthy men and women, 18 years of age or older, who have no history of significant medical conditions.
|
|
HIV positive
Men and women, 18 years of age or older, who have been diagnosed with HIV infection. Patients may be on or off of ARVs.
|
|
Parkinson's Disease
Men and women, 18 years of age or older, who have been diagnosed with Parkinson's Disease.
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Healthy controls, HIV positive (on or off ARVs), patients diagnosed with Parkinson's Disease.
All subjects must be 18 years of age or older.
Inclusion Criteria:
- 18 years of age or older
- healthy controls with no significant medical conditions
- diagnosed HIV positive patients on or off ARVs
- diagnosed Parkinson's Disease patients
- capacity to provide informed consent
Exclusion Criteria:
- none
Contacts and Locations| United States, California | |
| San Francisco General Hospital | |
| San Francisco, California, United States, 94110 | |
| Principal Investigator: | Marc Hellerstein, MD, PhD | Univeristy of California, Berkeley and University of California, San Francisco |
More Information
No publications provided
| Responsible Party: | Salena Killion, Lab Manager, KineMed |
| ClinicalTrials.gov Identifier: | NCT00990379 History of Changes |
| Other Study ID Numbers: | 6076 |
| Study First Received: | October 2, 2009 |
| Last Updated: | April 4, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by KineMed:
|
HIV brain diseases spinal fluid HIV positive |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Parkinson Disease Neurodegenerative Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Nervous System Diseases Movement Disorders Deuterium Oxide Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Radiation-Protective Agents Protective Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 16, 2013